Vitamin D Supplementation in Adults with Vitamin D Deficiency and Its Effect on Metabolic Syndrome - A Randomized Controlled Study.
Int J Vitam Nutr Res. 2018 Feb 22:1-6. doi: 10.1024/0300-9831/a000426. [Epub ahead of print]
Mahmood SF1, Idiculla J1, Joshi R2, Joshi S3, Kulkarni S1.
1 Medicine, St Johns National Academy of Medical Sciences, Bengaluru, India.
2 AIIMS, All India Institute of Medical Sciences, Bhopal, India.
3 Medicine, Joshi Hospital, Pune, India.
Probably only those getting vitamin D levels > 30 ng got a BMI reduction
- Waist size reduced 3 cm by Vitamin D in those with Metabolic Syndrome – Jan 2017
- Overweight and obese lost 12 lbs with vitamin D in 6 months– RCT May 2015
- Dieters lost 5 more pounds if achieved more than 32 ng of vitamin D – RCT March 2014
- 50,000 IU vitamin D weekly increased levels by 52 ng normally, but only 28 ng if obese – Oct 2013
- Obesity not reduced with 7,000 IU vitamin D daily – April 2013
Note: 60,000 IU/month in the study on the page = 2,000 IU daily, not nearly enough
Overview Obesity and Vitamin D contains the following summary
- FACT: People who are obese have less vitamin D in their blood
- FACT: Obese need a higher dose of vitamin D to get to the same level of vit D
- FACT: When obese people lose weight the vitamin D level in their blood increases
- FACT: Adding Calcium, perhaps in the form of fortified milk, often reduces weight
- FACT: 140 trials for vitamin D intervention of obesity as of Sept 2019
- FACT: Less weight gain by senior women with > 30 ng of vitamin D
- FACT: Dieters lost additional 5 lbs if vitamin D supplementation got them above 32 ng - RCT
- FACT: Obese lost 3X more weight by adding $10 of Vitamin D
- FACT: Those with darker skins were more likely to be obese Sept 2014
- SUGGESTION: Probably need more than 4,000 IU to lose weight if very low on vitamin D due to
risk factors such as overweight, age, dark skin, live far from equator,shut-in, etc.
- Obesity category has
- Normal weight Obese (50 ng = 125 nanomole)
Inverse relationship between metabolic syndrome (MetS) and 25-hydroxyvitamin D (25(OH) D) levels is controversial. Hypovitaminosis-D has long been suspected as a risk factor for glucose intolerance.
AIM:A randomized double blind placebo controlled study to evaluate effects of vitamin D supplementation on insulin resistance in subjects with hypovitaminosis-D and MetS.
MATERIALS AND METHODS:
Subjects were randomized to receive either oral 25(OH) D3 supplement (60000 (IU) per week for 8 weeks followed by 60,000 IU monthly for 4 months) or a placebo for six months. The parameters measured were blood pressure, vitamin D, fasting blood sugar (FBS), insulin, homeostasis model assessment (HOMA), quantitative insulin sensitivity check index (QUICKI), body mass index (BMI), and waist circumference (WC).
There were no significant changes in parameters of vitamin-D group compared to placebo group except serum vitamin-D was significantly increased in vitamin-D group (p < 0.0001). In vitamin-D group, mean WC at baseline was 95.9 ± 6.66, which significantly changed to 94.6 ± 7.47 (p = 0.001).
Mean BMI at baseline was 29.1 ± 4.06 which significantly changed to 28.5 ± 4.16 (p = 0.001). The mean vitamin-D concentration at baseline was 15.4 ± 9.03 which significantly (p < .0001) increased to 26.1 ± 11.8. In placebo group mean insulin levels was 10.7 ± 4.81IU / L which increased significantly (p = 0.03) to 15.4 ± 14.0. Mean QUICKI at baseline was 0.34 ± 0.03 which decreased significantly (p = 0.02) to 0.32 ± 0.03.
In this study the relationship between vitamin D supplementation and MetS or IR was not established. Whether achieving vitamin D sufficiency in large population-based trials with a longer duration would produce more favorable results needs to be assessed.
PMID: 29469682 DOI: 10.1024/0300-9831/a000426